BeOne Medicines SVP exercises options, trades ADS
BeOne Medicines Ltd. executive Lee Chan Henry, SVP and General Counsel, reported multiple option exercises and ADS trades on August 11, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BeOne Medicines Ltd. executive Lee Chan Henry, SVP and General Counsel, reported multiple option exercises and ADS trades on August 11, 2026. He exercised three option grants covering a total of 34,658 Ordinary Shares at exercise prices of $14.96, $16.41, and $12.23 per Ordinary Share. In related non-derivative transactions, he acquired blocks of 812, 1,058, and 796 American Depositary Shares (each ADS representing 13 Ordinary Shares), and sold 2,666 ADS at $360.00 per ADS pursuant to a Rule 10b5-1 trading plan adopted on May 29, 2026. Following these transactions, he directly held 325,312 Ordinary Shares.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option (Right to Buy) F3, F4 | 10,556 | $0.00 | $0.00 |
| Exercise | Share Option (Right to Buy) F3, F5 | 13,754 | $0.00 | $0.00 |
| Exercise | Share Option (Right to Buy) F3, F6 | 10,348 | $0.00 | $0.00 |
| Exercise | American Depositary Shares F1 | 812 | $194.47 | $158K |
| Exercise | American Depositary Shares F1 | 1,058 | $213.32 | $226K |
| Exercise | American Depositary Shares F1 | 796 | $159.03 | $127K |
| Sale | American Depositary Shares F1, F2 | 2,666 | $360.00 | $960K |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (6)
- F1. Each American Depositary Share represents 13 Ordinary Shares.
- F2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.
- F3. The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.
- F4. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
- F5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
- F6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
exercise price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did BeOne Medicines (ONC) report for Lee Chan Henry?
How many BeOne Medicines (ONC) options did Lee Chan Henry exercise and at what prices?
Was the BeOne Medicines (ONC) insider sale by Lee Chan Henry under a Rule 10b5-1 plan?
What are Lee Chan Henry’s reported holdings in BeOne Medicines (ONC) after these transactions?
AI-generated analysis. How Rhea-AI works. Not financial advice.